Literature DB >> 15761464

Origins and molecular pathology of ovarian cancer.

Debra A Bell1.   

Abstract

Epithelial ovarian cancer comprises the majority of malignant ovarian tumors in adult women. These neoplasms are classified into distinct morphologic categories based on the appearance of the epithelium into tumors of serous, mucinous, endometrioid, clear cell, transitional, squamous, mixed and undifferentiated type. Current data indicate that each of these histologic subtypes is associated with distinct morphologic and molecular genetic alterations: high-grade serous and possibly endometrioid carcinomas most probably arise from surface epithelial inclusion glands with TP53 mutations and dysfunction of BRCA1 and/or BRCA2; low-grade serous carcinomas probably arise in a stepwise fashion in an adenoma-borderline tumor-carcinoma sequence from typical to micropapillary borderline tumors to low-grade invasive serous carcinoma via activation of the RAS-RAF signaling pathway secondary to mutations in KRAS and BRAF; mucinous carcinomas arise via an adenoma-borderline tumor-carcinoma sequence with mutations in KRAS; low-grade endometrioid carcinomas arise from endometriosis via mutations in CTNNB1 (the gene encoding beta-catenin) and PTEN. Although the morphologic data strongly support an origin of clear cell carcinoma from endometriosis, there is limited data on the genetic alterations in these uncommon tumors. Thus it is likely that most low-grade, relatively indolent ovarian carcinomas of serous, mucinous and endometrioid type arise from pre-existing cystadenomas or endometriosis whereas most high-grade serous carcinomas arise without an easily identifiable precursor lesion.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15761464     DOI: 10.1038/modpathol.3800306

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  136 in total

Review 1.  Modern trends into the epidemiology and screening of ovarian cancer. Genetic substrate of the sporadic form.

Authors:  Maria Koutsaki; Apostolos Zaravinos; Demetrios A Spandidos
Journal:  Pathol Oncol Res       Date:  2011-12-09       Impact factor: 3.201

2.  Molecular Simulations of Solved Co-crystallized X-Ray Structures Identify Action Mechanisms of PDEδ Inhibitors.

Authors:  Ramin Ekhteiari Salmas; Mert Mestanoglu; Mine Yurtsever; Sergei Y Noskov; Serdar Durdagi
Journal:  Biophys J       Date:  2015-09-01       Impact factor: 4.033

Review 3.  Overcoming challenges of ovarian cancer stem cells: novel therapeutic approaches.

Authors:  Cristóbal Aguilar-Gallardo; Emily Cecilia Rutledge; Ana M Martínez-Arroyo; Juan José Hidalgo; Santiago Domingo; Carlos Simón
Journal:  Stem Cell Rev Rep       Date:  2012-09       Impact factor: 5.739

4.  Molecular profiling uncovers a p53-associated role for microRNA-31 in inhibiting the proliferation of serous ovarian carcinomas and other cancers.

Authors:  Chad J Creighton; Michael D Fountain; Zhifeng Yu; Ankur K Nagaraja; Huifeng Zhu; Mahjabeen Khan; Emuejevoke Olokpa; Azam Zariff; Preethi H Gunaratne; Martin M Matzuk; Matthew L Anderson
Journal:  Cancer Res       Date:  2010-02-23       Impact factor: 12.701

5.  Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial.

Authors:  Daniela Matei; Michael W Sill; Heather A Lankes; Koen DeGeest; Robert E Bristow; David Mutch; S Diane Yamada; David Cohn; Valerie Calvert; John Farley; Emanuel F Petricoin; Michael J Birrer
Journal:  J Clin Oncol       Date:  2010-11-22       Impact factor: 44.544

6.  Acquisition of a second mutation of the Tp53 alleles immediately precedes epithelial morphological transformation in ovarian tumorigenicity.

Authors:  Kathy Q Cai; Hong Wu; Andres J Klein-Szanto; Xiang-Xi Xu
Journal:  Gynecol Oncol       Date:  2009-04-16       Impact factor: 5.482

7.  Single-cell EMT-related transcriptional analysis revealed intra-cluster heterogeneity of tumor cell clusters in epithelial ovarian cancer ascites.

Authors:  Tongtong Kan; Wei Wang; Philip P Ip; Shengtao Zhou; Alice S Wong; Xin Wang; Mengsu Yang
Journal:  Oncogene       Date:  2020-04-13       Impact factor: 9.867

8.  TP53 mutations, tetraploidy and homologous recombination repair defects in early stage high-grade serous ovarian cancer.

Authors:  Jeremy Chien; Hugues Sicotte; Jian-Bing Fan; Sean Humphray; Julie M Cunningham; Kimberly R Kalli; Ann L Oberg; Steven N Hart; Ying Li; Jaime I Davila; Saurabh Baheti; Chen Wang; Sabine Dietmann; Elizabeth J Atkinson; Yan W Asmann; Debra A Bell; Takayo Ota; Yaman Tarabishy; Rui Kuang; Marina Bibikova; R Keira Cheetham; Russell J Grocock; Elizabeth M Swisher; John Peden; David Bentley; Jean-Pierre A Kocher; Scott H Kaufmann; Lynn C Hartmann; Viji Shridhar; Ellen L Goode
Journal:  Nucleic Acids Res       Date:  2015-04-27       Impact factor: 16.971

9.  A link between mir-100 and FRAP1/mTOR in clear cell ovarian cancer.

Authors:  Ankur K Nagaraja; Chad J Creighton; Zhifeng Yu; Huifeng Zhu; Preethi H Gunaratne; Jeffrey G Reid; Emuejevoke Olokpa; Hiroaki Itamochi; Naoto T Ueno; Shannon M Hawkins; Matthew L Anderson; Martin M Matzuk
Journal:  Mol Endocrinol       Date:  2010-01-15

10.  The role of components of the chromatin modification machinery in carcinogenesis of clear cell carcinoma of the ovary (Review).

Authors:  Hiroshi Shigetomi; Akira Oonogi; Taihei Tsunemi; Yasuhito Tanase; Yoshihiko Yamada; Hirotaka Kajihara; Yoriko Yoshizawa; Naoto Furukawa; Shoji Haruta; Shozo Yoshida; Toshiyuki Sado; Hidekazu Oi; Hiroshi Kobayashi
Journal:  Oncol Lett       Date:  2011-05-16       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.